PMID: 7537286Feb 1, 1995Paper

Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study

Journal of Clinical Psychopharmacology
G Chouinard

Abstract

In the Canadian multicenter, double-blind clinical trial of risperidone, 135 hospitalized chronic schizophrenic patients were randomly assigned to one of six parallel treatment groups for 8 weeks: risperidone, 2, 6, 10, or 16 mg/day; haloperidol, 20 mg/day; or placebo. Risperidone (6 to 16 mg)-treated patients showed significantly (p < 0.05) lower dyskinetic scores than those receiving placebo, whereas in haloperidol- and placebo-treated patients, no significant differences for dyskinetic symptoms were noted. To explore the antidyskinetic effect of risperidone, a post hoc analysis was performed on two selected patient samples: (1) patients meeting Research Diagnosis Criteria (RDC) for tardive dyskinesia (TD) at baseline or during double-blind treatment (N = 49) and (2) patients with RDC TD and with a Clinical Global Impression (CGI) Severity of dyskinesia score > or = 5 (at least moderately severe) (N = 48). The composition of the two subsamples was found to be almost identical because all but one of the patients with RDC TD (N = 49) were members of the group with at least moderately severe TD (N = 48). Analysis of four parameters (Extrapyramidal Symptom Rating Scale-dyskinesia total score, CGI severity of dyskinesia, buccoling...Continue Reading

Citations

Jan 12, 2012·Psychopharmacology·Philippe CorbeilEmmanuelle Pourcher
Jul 17, 2007·European Archives of Psychiatry and Clinical Neuroscience·Michael RiedelHans-Jürgen Möller
Jan 31, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jovan SimeonSelena Walker
May 3, 2003·Brain Research Bulletin·R C CarvalhoR Frussa-Filho
Apr 6, 1999·Schizophrenia Research·D E Casey
Jun 8, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·Pierre-Michel LlorcaChristophe Lancon
Jan 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·P SakkasG N Christodoulou
Nov 26, 1999·European Psychiatry : the Journal of the Association of European Psychiatrists·L LykourasG N Christodoulou
Mar 12, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nadeem H BhanjiHoward C Margolese
Jul 10, 2003·Lancet Neurology·Raúl de la Fuente-FernándezA Jon Stoessl
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
Sep 8, 2010·The Journal of Clinical Psychiatry·Stanley N CaroffUNKNOWN CATIE Investigators
Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Leslie J CloudStewart A Factor
Jun 17, 2003·Journal of the American Medical Directors Association·Richard J Goldberg
Feb 25, 2005·International Clinical Psychopharmacology·Ya-Mei BaiChao-Cheng Lin
Nov 11, 2003·Current Medical Research and Opinion·Ibrahim S Al-ZakwaniTara R Cockerham
Nov 3, 2010·L'Encéphale·C DemilyG Chouinard
Jun 14, 2005·Schizophrenia Research·Guy Chouinard, Howard C Margolese
Apr 27, 2017·Expert Opinion on Pharmacotherapy·Daniel P WitterUma Suryadevara
Jun 26, 2017·Psychotherapy and Psychosomatics·Guy ChouinardMasaomi Iyo
May 5, 2000·The Cochrane Database of Systematic Reviews·E KennedyS Gilbody
Feb 7, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Sep 21, 2000·Psychiatry and Clinical Neurosciences·H TachikawaH Shiraishi
Nov 19, 2013·The Cochrane Database of Systematic Reviews·Clive E AdamsStephen Lawrie
Sep 8, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·T Scott Stroup, Neil Gray
Dec 4, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael WagnerKai-Uwe Kühn
Feb 7, 2007·Current Opinion in Psychiatry·Gary Remington
Jul 2, 2005·Journal of Psychiatric Practice·J C ChouM Serper
Jan 1, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·K A Gwinn, J N Caviness
Jan 27, 2006·The Cochrane Database of Systematic Reviews·K Soares-Weiser, J Rathbone
Oct 13, 2009·The Cochrane Database of Systematic Reviews·Chunbo LiJijun Wang
Aug 16, 2017·Health Technology Assessment : HTA·Hanna BergmanClive E Adams
Dec 16, 2016·The Cochrane Database of Systematic Reviews·Ranganath D RattehalliStephanie Sampson
Jul 29, 2017·Expert Review of Neurotherapeutics·Haitham SalemAntonio L Teixeira
Jun 17, 2011·The Cochrane Database of Systematic Reviews·John BolaHaluk Soydan
Aug 26, 2020·The Cochrane Database of Systematic Reviews·Anna CerasoStefan Leucht
Feb 23, 2019·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Lucia RicciardiMark Edwards

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here